Compare Neurocrine Biosciences Inc (NBIX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wheaton Precious Metals Corp — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Wheaton Precious Metals Corp trades at $110.88 (market cap $46.54B). The key difference: Wheaton Precious Metals Corp is far larger — about 2.7× Neurocrine Biosciences Inc's market cap, and Wheaton Precious Metals Corp pays a 0.75% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WPM | |
|---|---|---|
Market Cap | $17.40B | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $180.55 | $165.72 |
52-Week Low | $123.10 | $91.00 |
Enterprise Value | $16.49B | $44.39B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Wheaton Precious Metals (WPM) trades at $109.96, up 5.55% today, with a bearish technical signal but strong fundamentals. The company reported record revenue of $2.31B in 2025, net income of $1.47B, and has beaten earnings estimates for three consecutive quarters. Operating cash flow surged to $1.90B in 2025, supporting a positive outlook.
WPM offers growth potential with an 80% analyst buy rating and a consensus price target of $161.75, implying significant upside. Risks include exposure to precious metal price volatility and a high P/E ratio of 26.14. The stock's current discount to target presents a buying opportunity for long-term investors, contingent on stable metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
